CTMX

Company Overview — What Does CytomX Therapeutics, Inc. Do?

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California. CytomX Therapeutics, Inc. (CTMX) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Sean A. McCarthy and employs approximately 170 people, headquartered in SOUTH SAN FRANCISCO, California. With a market capitalization of $986M, CTMX is one of the notable companies in the Healthcare sector.

CytomX Therapeutics, Inc. (CTMX) Stock Rating — Reduce (April 2026)

As of April 2026, CytomX Therapeutics, Inc. receives a Reduce rating with a composite score of 40.3/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.CTMX ranks #2,981 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, CytomX Therapeutics, Inc. ranks #427 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

CTMX Stock Price and 52-Week Range

CytomX Therapeutics, Inc. (CTMX) currently trades at $4.41. The stock gained $0.17 (4.1%) in the most recent trading session. The 52-week high for CTMX is $8.21, which means the stock is currently trading -46.3% from its annual peak. The 52-week low is $0.40, putting the stock 1003.0% above its annual trough. Recent trading volume was 3.2M shares, reflecting moderate market activity.

Is CTMX Overvalued or Undervalued? — Valuation Analysis

CytomX Therapeutics, Inc. (CTMX) carries a value factor score of 32/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The trailing price-to-earnings ratio is 62.48x, compared to the Healthcare sector average of 23.63x — a premium of 164%. The price-to-book ratio stands at 9.39x, versus the sector average of 2.75x. The price-to-sales ratio is 8.53x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, CTMX trades at 96.05x EV/EBITDA, versus 6.34x for the sector.

At current multiples, CytomX Therapeutics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

CytomX Therapeutics, Inc. Profitability — ROE, Margins, and Quality Score

CytomX Therapeutics, Inc. (CTMX) earns a quality factor score of 28/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 15.0%, compared to the Healthcare sector average of -43.5%, which is within a healthy range. Return on assets (ROA) comes in at 9.8% versus the sector average of -33.1%.

On a margin basis, CytomX Therapeutics, Inc. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -53.6% (sector: -66.1%). Net profit margin stands at -44.0%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -76.3% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

CTMX Debt, Balance Sheet, and Financial Health

CytomX Therapeutics, Inc. has a debt-to-equity ratio of 53.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 3.09x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $34M.

CTMX has a beta of 2.37, meaning it is more volatile than the broader market — a $10,000 investment in CTMX would be expected to move 136.5% more than the S&P 500 on any given day. The stability factor score for CytomX Therapeutics, Inc. is 14/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

CytomX Therapeutics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, CytomX Therapeutics, Inc. reported revenue of $109M. Net income for the quarter was $15M. Gross margin was 100.0%. Operating income came in at $10M.

In FY 2025, CytomX Therapeutics, Inc. reported revenue of $76M. Net income for the quarter was $-17M. Revenue grew -44.8% year-over-year compared to FY 2024. Operating income came in at $-22M.

In Q3 2025, CytomX Therapeutics, Inc. reported revenue of $6M. Net income for the quarter was $-14M. Revenue grew -82.2% year-over-year compared to Q3 2024. Operating income came in at $-16M.

In Q2 2025, CytomX Therapeutics, Inc. reported revenue of $19M. Net income for the quarter was $-154,000. Revenue grew -25.7% year-over-year compared to Q2 2024. Operating income came in at $-1M.

Over the past 8 quarters, CytomX Therapeutics, Inc. has demonstrated a growth trajectory, with revenue expanding from $25M to $109M. Investors analyzing CTMX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

CTMX Dividend Yield and Income Analysis

CytomX Therapeutics, Inc. (CTMX) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

CTMX Momentum and Technical Analysis Profile

CytomX Therapeutics, Inc. (CTMX) has a momentum factor score of 73/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 39/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 36/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

CTMX vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, CytomX Therapeutics, Inc. (CTMX) ranks #427 out of 838 stocks based on the Blank Capital composite score. This places CTMX in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing CTMX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full CTMX vs S&P 500 (SPY) comparison to assess how CytomX Therapeutics, Inc. stacks up against the broader market across all factor dimensions.

CTMX Next Earnings Date

No upcoming earnings date has been announced for CytomX Therapeutics, Inc. (CTMX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy CTMX? — Investment Thesis Summary

The quantitative profile for CytomX Therapeutics, Inc. suggests caution. The quality score of 28/100 flags below-average profitability. The value score of 32/100 indicates premium valuation. Price momentum is positive at 73/100, suggesting the trend favors buyers. High volatility (stability score 14/100) increases portfolio risk.

In summary, CytomX Therapeutics, Inc. (CTMX) earns a Reduce rating with a composite score of 40.3/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on CTMX stock.

Related Resources for CTMX Investors

Explore more research and tools: CTMX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare CTMX head-to-head with peers: CTMX vs AZN, CTMX vs SLGL, CTMX vs VMD.